drugset / Trial / NCT03873402

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

NCT03873402

Phase 3 Active not recruiting 437 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.

Timeline

Start
2019-06-21
Primary completion
2027-03-11
Completion
2027-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody
Background Nivolumab Monoclonal antibody

Indications